Merit Medical Systems DCF Stock Analysis. Buy or Sell?

Merit Medical Systems DCF Stock Analysis.

In partnership with

The free newsletter making HR less lonely

The best HR advice comes from people who’ve been in the trenches.

That’s what this newsletter delivers.

I Hate it Here is your insider’s guide to surviving and thriving in HR, from someone who’s been there. It’s not about theory or buzzwords — it’s about practical, real-world advice for navigating everything from tricky managers to messy policies.

Every newsletter is written by Hebba Youssef — a Chief People Officer who’s seen it all and is here to share what actually works (and what doesn’t). We’re talking real talk, real strategies, and real support — all with a side of humor to keep you sane.

Because HR shouldn’t feel like a thankless job. And you shouldn’t feel alone in it.

Merit Medical Systems’ DCF Stock Analysis

Here’s my assumptions for $MMSI ( ▲ 2.51% ) :

Risk Free Rate (10 Years Interest Rate Swap): 4.13%

Risk Premium (Taken from the Aswath Damodaran equity premium spreadsheet): 4.33%

Interest Rate Spread on The Risk free rate ( For the cost of debt calculation): 4%

Historical Data

Revenue growth in the last 10 years (CAGR): 9.61%

Earnings growth in the last 10 years (CAGR): 17.60%

Unlevered Free Cash Flow growth in the last 10 years (CAGR): 36.59%

Future Assumptions

End of Year FCF growth: 15%

Growth until end of 2026: 25%

Growth until end of 2034: 15%

Perpetual growth: 3%

Net Debt: 0.422B

Outstanding Stock Options Present Value Assumption: $0.049B

Restricted Stock Units + Performance Stock Units Present Value Assumption: $0.077B

Stock Valuation based on these assumptions: $255

Last update 07/25/2025

All the content in this newsletter should be taken as informational content only. THIS IS NOT FINANCIAL ADVICE! Do your own Due Diligence before investing or contact a professional financial advisor.

I don’t have a position in Merit Medical Systems (MMSI) and I don’t plan to add a position in the coming days.